NCT06028074 - Safety and Tolerability Study of GIM-122 in Subjects With Advanced Solid Malignancies | Biotech Hunter

Enrollment

111

Participants

Timeline

Start Date

December 12, 2023

Primary Completion Date

September 30, 2026

Study Completion Date

December 31, 2026

Conditions

Advanced Solid Malignancies

Interventions

DRUG

GIM122

GIM-122 administered IV once every 3 weeks or every 2 weeks

Trial Locations (11)

23298

RECRUITING

Virginia Commonwealth University, Richmond

34232

RECRUITING

Florida Cancer Specialists, Sarasota

37203

RECRUITING

Tennessee Oncology, PLLC, Nashville

40202

RECRUITING

Norton Cancer Institute, Louisville

75039

RECRUITING

NEXT Oncology Dallas, Irving

75246

RECRUITING

Texas Oncology - Baylor Sammons Cancer Center, Dallas

90025

RECRUITING

The Angeles Clinic and Research Institute, Los Angeles

90033

RECRUITING

USC/Norris Comprehensive Cancer Center, Los Angeles

90095

RECRUITING

UCLA Hematology/Oncology, Los Angeles

94143

RECRUITING

UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco

08903

RECRUITING

Rutgers Cancer Institute of NJ, New Brunswick